102 results about "Drug capsule" patented technology

An automated injection module is comprised of a housing, a piston drug capsule disposed within the housing, a piston core including a puncture seal membrane defining a reservoir for holding a drug between the puncture seal membrane and the piston drug capsule, an injection device having at least one sharp end for puncturing the puncture seal upon activation of the device, an end cap on a distal end of the housing, and a pressure source on a proximal end of the housing. The pressure source is preferably a propellant that ignites and forces the piston toward the distal end. Substantially simultaneously, the injection device pierces the puncture seal membrane, the piston core is forced into the piston drug capsule, and the drug is evacuated from the reservoir through the injection device and into a patient.

An improved upper capsule portion (62) of an oral drug delivery capsule (60) that includes an upper capsule portion (62) and a lower cup shaped capsule portion (64), the lower cup shaped capsule portion (64) containing a medical formulation (66), the lower capsule portion (64) being made of a material that disperses in gastrointestinal fluid, the lower capsule portion (64) having a mouth, the upper capsule portion (62) dimensioned to engage with the mouth of the lower capsule portion (64). The improvement is the positioning of a communication device, such as an RFID tag (90), on or integrally with the upper capsule portion (62) so that the communication device can communicate that the oral drug delivery capsule has been ingested. An alternate embodiment with an improved lower capsule portion is also disclosed.

A method for filling needleless injector capsules with liquid drug, whereby dissolved gas within the drug is replaced by a less soluble gas in order to reduce the inclusion of gas bubbles, or to prevent the growth of bubbles during storage and thereby prevent breakage of the capsules.

The present invention relates to a preparation method of new-type medicine capsule-plant capsule. It is characterized by that it adopts conventional capsule production method, uses the gelatin capsule production machine and utilizes natural plant cellulose derivative-cellulose ether as raw material to produce the invented plant capsule.

The invention relates to a swallowable medication capsule capable 200 of dispensing fluid medicine stored in a medication compartment 211 through a valveless exit holt 207. A vent hole 206 enables ventilation of an actuator cavity 212 which houses an actuator used for displacing a surface 205 which separates the medication cavity 211 and the actuator cavity 212. By locating the vent and exit holes close to each other so that contact with contracting parts of the gastrointestinal tract and the exterior surface 221 is not able to prohibit a pressure passageway between the vent and exit holes, creation of a pressure difference of pressures in the medication and actuator cavity is prohibited.

A pharmaceutical capsule container comprises (i) a novel vial having a closed-bottom window formed from a transparent polymer, and a side-wall formed from a light-blocking polymer, and (ii) a safety cap. The vial is made as one piece by dual injection molding. The window serves as a clear-view window through which a pharmacist may view capsules inside a closed capsule container. In a preferred embodiment the window serves as a magnifying lens for easier recognition of capsule indicia. A pharmacist uses the invention to re-verify the type and strength of the capsules in a filled, closed capsule container against the type and strength specified in the prescription by viewing the capsules in the filled, closed capsule container. The pharmacist holds the capsule container upright and looks up to view the capsules in the container through the window in the bottom of the vial This enables the pharmacist to re-verify a prescription without being required to remove and replace the safety cap every time a prescription is filled.

The invention relates to a preparation method of a water-insoluble drug microcapsule. The water-insoluble drug microcapsule is a capsule with a multi-layer shell structure, and the wall of the water-insoluble drug microcapsule consists of a water-insoluble drug and a membrane layer formed by alternating deposition of a plurality of layers of polyelectrolyte with opposite charges. The preparation steps are as follows: 1), at first, preparing a soluble template microsphere with the surface thereof absorbed with a plurality of polyelectrolyte membranes; 2) then, removing the soluble template microsphere to prepare a hollow polyelectrolyte capsule; and 3), finally, loading the water-insoluble drug in the hollow polyelectrolyte capsule. The insoluble drug microcapsule prepared in the method has the advantages of uniform size, high drug solubility, controllable drug releasing rate and good dispersibility in various kinds of aqueous solution, and can also be connected with biologically active substances, such as antibodies, antigens, enzymes, proteins or nucleic acid, in order to achieve drug targeting.

The invention discloses a flexible microneedle drug delivery patch containing a separable drug capsule suitable for transdermal delivery of multiple drugs. The microneedle drug delivery patch has the advantages that pain level is low, infection risk is low and application is convenient. The microneedle drug delivery patch comprises the separable and replaceable drug capsule, a drug carrying end integrating a microneedle array with a microfluid flow passage network, a drug delivering end integrating the microneedle array with the microfluid flow passage network, and a sticky patch body allowing the microneedle drug delivery patch to be attached to skin, wherein the sticky patch body is made from a flexible polymer and is high in curvature and skin bonding property. In use, the drug delivery patch is attached to a joint of a user, the drug carrying end and the drug capsule of the drug delivery patch deform under the squeezing and stretching actions of the bent joint on the flexible microneedle drug delivery patch, so that a syringe needle at the drug carrying end pierces into the drug capsule and drugs are distributed to the drug delivering end through the microfluid flow passage network, and then drugs flow into the body through a passage formed on skin by a microneedle at the drug delivering end to finish drug delivery.

An inhaler (1) device for inhalation of a medicament from a pierceable capsule (10) comprises a housing (2) for receiving a medicament, capsule, closure means (3) for closing the housing, said closure means being moveable relative to the housing; piercing means (7) suitable for piercing a medicament capsule; wherein movement of the closure means relative to the housing causes movement of the piercing means, and wherein the device comprises an air inlet (71) and an air outlet (72) defining an inhalation passage therebetween, the passage comprising one or more vents (70).

Embodiments of the invention provide drug packaging and methods for producing drug packaging which can be sealed at room temperature and / or without the need for elevated temperatures above room temperature. Many embodiments provide drug packaging comprising pierceable tubing having a capsule shape (also referred to herein as a pierceable capsule and / or pierceable drug capsule) containing a solid drug such as a drug pellet and methods for producing pierceable drug capsules which can be sealed at room temperature. Embodiments are particularly useful for the packaging and delivery of drugs used in implantable drug delivery devices as well as packaging of drugs that are easily thermally degraded.

The invention relates to a preparation method of camptothecin drug slow release microcapsule. Firstly, camptothecin drug microcrystal is positioned into deionized water for ultra sonic dispersion, secondly, the dispersed camptothecin drug microcrystal is positioned into polycation solution for adsorption, centrifugation and washing, third, the camptothecin drug microcrystal adsorbing the polycation is positioned into polyanion solution for adsorption, centrifugation and washing, then the step two and the step three are repeated, and thereby the drug microcapsule with core-shell structure is obtained. The microcapsule is very stable, can realize controlled release of the drug, can be produced to be micron-nanometer drug oral liquid or injection, and also can be produced to be drug capsule, and tablets, etc. The process of the invention is simple, the reaction condition is mild, the operation is easy, the reproducibility is good, the environment is protected, the invention provides substantial foundation and technical support for the application and the research of the camptothecin and other drugs having the characteristics of high curative effect, but large toxicity and poor water solubility, and has good application prospect.

Disclosed is a method for preparing 'Wei Kang Ling' capsule which consists of white peony root 317.5g, hyacinth bletilla 238.1g, notoginseng 9.9g, licorice 317.2g, poria 238.1g, corydalis tuber 158.7g and cuttlebone 31.7g, belladonna 2.1g and medicinal adjuvant. The invention improves the powder property of capsule content and reduces the difference of loading capacity by modifying the process.

A method of flowing a medicament comprising dry powder using gas, including preparing a medicament capsule with designated inflow and outflow apertures, introducing a volume of a gas to within a medicament capsule according to one or more release conditions, and releasing a therapeutically effective amount of said powder using said gas. In some embodiments, the medicament capsule apertures are prepared and / or gas delivered to it so that deagglomeration potentially occurs largely within the energetic flow conditions of the capsule, without significant trapping of residual powder by structures such as aperture edge irregularities.

The invention provides an anti-drug capsule prepared from pure traditional Chinese medicines, which comprises the following traditional Chinese medicines in parts by weight: 10-30 parts of smallflower milkwort herb with root, 10-30 parts of maggot, 10-30 parts of ginseng, 10-30 parts of rhubarb, 10-30 parts of prepared scorpion, 10-30 parts of milk vetch, 10-30 parts of scorpion, 10-30 parts of corydalis tuber, 10-30 parts of angelica, 10-30 parts of prepared aconite root, 10-30 parts of cassia twig, 10-30 parts of bupleurum, 10-30 parts of gastrodia tuber, 10-30 parts of clematis root, 10-30 parts of angelica, 10-30 parts of white peony root, 10-30 parts of eucommia, 10-30 parts of pseudo-ginseng, 10-30 parts of safflower, 10-30 parts of american lopseed and 10-20 parts of licorice. The anti-drug capsule provided by the invention has the advantages of no toxic side effects, short treatment time and low cost; and the anti-drug capsule can also be used for comprehensively conditioning the body of a druggy and improving the immunity of the body, so that the druggy can realize drug rehabilitation and can recover simultaneously. After the anti-drug capsule is taken by 20 patients clinically, the patients have no adverse reactions; after the anti-drug capsule is taken by a patient for 7 days, the patient has ruddy complexion and pleasant mood and likes exercising, the mental state of the patient is the same as the mental state of a normal person, the weight of the patient obviously increases, and the patient has no craving for drugs; and after a course of treatment (10 days), morphine detection is carried out, and the detection result is negative. The effective rate of the anti-drug capsule is 100%.

The invention relates to a medical polymer material, in particular to a modified soybean protein empty capsule material and a preparation method thereof and belongs to the technical field of pharmaceutic adjuvants. The modified soybean protein empty capsule material comprises components in parts by mass as follows: 60-85 parts of modified soybean protein, 10-35 parts of edible colloid, 0.5-2.0 parts of an emulsifier and 0.5-2.0 parts of a cross-linking agent. The modified soybean protein empty capsule material has the advantages that the modified soybean protein empty capsule material has an excellent film-forming property; compared with a conventional plant capsule material, the modified soybean protein empty capsule material doesn't contain any animal gelatin additives, is safer and more reliable and is incomparable to other materials used for preparing empty capsule. Besides, all kinds of soft or hard capsule prepared from the modified soybean protein empty capsule material serving as a pharmaceutic adjuvant have stable performance, low cost and no side effect, the efficacy of a drug cannot be affected, the material has excellent adaptability to conventional capsule equipment, special equipment modification or addition is not required, and the application potential is huge.

The present invention discloses a traditional Chinese medicine preparation for treating migraine and trigeminal neuralgia. A purpose of the present invention is to design a migraine and trigeminal neuralgia treatment traditional Chinese medicine preparation with characteristics of good treatment effect and low processing cost. The technical scheme is: (1) selecting ginseng, angelica, safflower, szechwan lovage rhizome, prepared common monkshood mother root, divaricate saposhnikovia, doubleteeth angelica root, ovientvine stem, papaya and semen ziziphi spinoae, (2) taking the ginseng and the safflower, and crushing into fine powder to be spare, and (3) taking the remaining 8 traditional Chinese medicines, crushing into coarse powder, adding water to carry out boiling extraction three times, mixing the boiling liquids, filtering, concentrating, carrying out vacuum drying, crushing into fine powder to be spare, uniformly mixing the two fine powders, and filling into drug capsules to complete preparation. The traditional Chinese medicine preparation has characteristics of satisfactory use effect, effective migraine and trigeminal neuralgia treatment, and low medication cost, and is suitable for promotion use.

The present invention relates to pharmaceutical capsule compositions comprising the compound niraparib as an active pharmaceutical ingredient, suitable for oral administration as well as to methods for their preparation. Also described herein are capsule formulations containing niraparib formed by the disclosed methods, and therapeutic uses of such capsule formulations for treating various disorders and conditions. The niraparib is distributed with substantial uniformity throughout a pharmaceutically acceptable carrier of the capsule formulations and exhibit good long-term stability and dissolution properties.

The invention discloses a noble metal / zinc oxide compound nano-hollow sphere and a preparation method thereof. The diameter of the hollow sphere is 10 to 35nm, the thickness of a spherical shell is 1 to 6nm and noble metal particles with the particle size of 1 to 3nm are embedded on the inner wall of the sphere; the preparation method comprises the following steps of: firstly, mixing sodium dodecyl sulfate and water to obtain sodium dodecyl sulfate solution with the concentration of 0.01 to 0.1 M, and then arranging a zinc plate into the sodium dodecyl sulfate solution under stirring; secondly, using laser with the wavelength of 1064nm, the power of 35 to 100mJ / pulse, the frequency of 5 to 15Hz and the pulse width of 5 to 15ns to irradiate the zinc plate for 50 to 70min to obtain zinc / zinc oxide colloid; and thirdly, dripping noble metal acid solution with the concentration of 1 to 5mM in the zinc / zinc oxide colloid under stirring to obtain products, then carrying out washing and drying to the products and preparing the noble metal / zinc oxide compound nano-hollow sphere. The noble metal / zinc oxide compound nano-hollow sphere can greatly improve the performance and application in the aspects of pharmaceutical capsules, sensors, batteries, optical devices, catalysts, biology and the like.

The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and / or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.

The invention discloses a drug capsule to cure intestines disease and sinusitis, and the preparing method, using Common Andrographis Herb and Climbing Groundsel Herb as main raw material, associated with micronized silica gel. It is applied to symptoms such as enteritis, colonitis, bacteroidal dysentery and sinusitis, has better curative effect on the patient suffering sinusitis whose course of diseases is short and whose middle nose channel have no rhinopolypus, has good curative effect on the patient suffering from acute diarrhea, acute dysentery and acute enteritis, especially the patient taking other medicine to cause maladjustment of bacteric crowd to produce side-effect. It has functions of cleaning heat and detoxifying, diminishing inflammation and acesodyne, and anti-diarrhoea. It better preserves effective substance in medicinal materials, shelf life up to above two years and having advantages of good stability, accurate curative effect, saving time, low cost, etc.

The invention discloses application of artemisinin in preparation of drugs for resisting human liver cancer HepG2 and Huh7 cells. The purpose is achieved by inhibiting proliferation of the human livercancer HepG2 and Huh7 cells, and / or adjusting the expression profile of miRNA in the human liver cancer HepG2 and Huh7 cells. The concentration of the artemisinin is lower than or equal to 100 micromoles; the drugs are in an electuary dosage form or a capsule dosage form. The invention further discloses a drug electuary which contains the artemisinin and resists the human liver cancer HepG2 and Huh7 cells, a drug capsule which contains the artemisinin and resists the human liver cancer HepG2 and Huh7 cells and preparation method of the drug capsule. Under the effect of the artemisinin drugs,the proliferation of the human liver cancer HepG2 and Huh7 cells is inhibited, changes of the expression profile of the miRNA in the human liver cancer HepG2 and Huh7 cells are adjusted and controlled, the miRNA potentially adjusting and controlling the liver cancer is discovered, and the foundation is laid for strategic development of the artemisinin in the aspect of liver cancer treatment.

The invention relates to a placenta immunity adjusting medicine capsule with each medical dose unit containing 1 / 50 to 1 / 10000mL placenta tissue fluid. A poultry egg serves as an attachment agent and is added with the placenta tissue fluid for full agitation. The solution is dried and then crushed into powder which is then put into capsules. The medicine capsule can stimulate the immunity action, thus achieving the aim of health care and curing and preventing diseases. As the amount of the effective ingredients is small, no adverse drug reaction is occurred. Seen through the treatment to prostatomegaly urinary retention, nephritis, epilepsy, inflammatory aches, Meniere disease, etc., the capsule achieves good result.

The invention provides a drug capsule for treating gallbladder disease and a preparation method thereof. The drug capsule is a compound preparation combining traditional Chinese medicine with Western medicine and having good treatment effect. The drug capsule is prepared by processing oriental wormwood, longhairy antenoron herb, Chinese violet, curcuma root, loofah sponge and magnesium sulfate serving as raw materials. The drug capsule contains metabolic substances capable of dredging meridians and collaterals of liver and gall, inducing choleresis and discharging intraheptic stasis. 'Lu su Asking, Six Viscera State Theory' says that all eleven internal organs depend on gall. 64.7% of out-patients in twenty years have liver and gall disease through ear-point electrodiagnosis, and gall disease accounts for 97.3% while liver disease accounts for 2.7%. 53 chronic diseases are caused by functional disorder of gall and liver. The pathological mechanism is disorder in qi-blood circulation. 'Coffin, Meridian Ten' says that meridians can decide life and death, cure all diseases and regulate deficiency and excess, and have to be dredged. Practice of 20 years verifies that scientificity and practicability of the Meridian-Collateral Theory of traditional Chinese medicine are further verified, and disease entities and disease cases are attached.

A drug capsule and a method for making a drug capsule for a drug delivery device, such as an auto injector or needle-free injector, with improved stability and container closure integrity. The injector comprises a drug capsule sealed by a piston fabricated from PTFE modified by the inclusion of a co-polymer of PPVE, preferably in an amount less than 1% by weight, resulting in better performance while the device is stored and subjected to temperature cycling.

The invention belongs to the field of nano-drugs, and particularly relates to a synthesis method of a hollow mesoporous silicon dioxide nano-drug capsule. The synthesis method comprises the following steps: modifying hollow mesoporous silicon dioxide through an acrylic acid propyl ester group, dispersing the hollow mesoporous silicon dioxide into a drug-containing buffer solution, then adding polyethylene glycol diacrylate and ammonium persulfate serving as an initiator, and dripping N,N,N',N'-tetramethylethylenediamine serving as an accelerator to enable the polyethylene glycol diacrylate and the acrylic acid propyl ester group to generate polymerization reaction on the surface of the hollow mesoporous silicon dioxide to form a polymer coated layer. Loading of a drug and encapsulation of a nano capsule are completed in the drug-containing buffer solution, so that leakage of the drug in an encapsulation process can be avoided; the synthesis process is simple, and the coating thickness and the compactness can be adjusted.

Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.

The invention discloses a novel fatty liver treatment drug preparation device which comprises a fixed base. A conveying table extends forwards or backwards and is arranged in the middle of the upper end surface of the fixed base, a grinding box is arranged above the fixed base, grinding space is arranged in the grinding box, a drug filling device is arranged on the lower end surface of the grinding box and comprises a fixed shell fixedly connected with the grinding box, a movable shell is arranged at the lower end of the fixed shell, the fixed shell is fixedly connected with the movable shellthrough an annular rubber sleeve, the fixed shell, the movable shell and the rubber sleeve collectively form the inner drug filling space, and a drug distributing device is arranged at the inner lowerend of the drug filling space. When the device works, grinding is accelerated, production efficiency is high, each capsule is filled with drugs, so that the qualification rate of drug capsule finished products is ensured, sprinkling of the drug is avoided, production cost is saved, and waste of raw materials is effectively reduced.

The invention discloses a novel drug capsule processing method which comprises the following steps: 1, selecting raw materials; 2, preparing a capsule liquid; 3, making capsule bodies; 3, demolding the capsule bodies; 5, performing subsequent treatment; 6, inspecting and packaging. In the step 1, the raw materials comprise the following components in percentage by mass: 20-30% of pharmaceutical gelatin, 8-10% of hydroxypropyl methylcellulose, 10-20% of a starch mixture, 8-10% of carrageenan, 5-10% of pectin, 5-8% of tragacanth, 10-15% of Arabic gum and 10-20% of an alcohol mixture. The materials are weighed according to the sum 1 of the weight percent. According to the novel drug capsule processing method, the processed capsule is smooth in surface, uniform in color, high in stability, reasonable in moisture content and difficult to break or soften; due to the addition of the tragacanth and the Arabic gum, the elasticity of the capsule is greatly increased, the capsule is convenient topreserve, and the storage life is greatly prolonged.

The invention relates to a medical polymer material, in particular to a modified soybean protein hollow capsule material and a preparation method thereof, which belongs to the technical field of pharmaceutical excipients, and includes the following components and mass ratio: modified soybean protein: 60~ 85 parts; edible gum: 10-35 parts; emulsifier: 0.5-2.0 parts; Compared with traditional vegetable capsule materials, it does not contain any animal gelatin additives, and is safer and more reliable, which is unmatched by hollow capsules made of other materials. In addition, all kinds of soft and hard capsules prepared with it as pharmaceutical excipients have stable performance, low cost, no side effects, and will not affect the efficacy of drugs. They have good adaptability to traditional drug capsule equipment and do not require special Equipment modification or addition, the application potential is huge.